Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment
Abstract Adipose tissue-derived mesenchymal stromal/stem cells (ADMSCs) represent a novel therapeutic intervention for Type 1 Diabetes (T1D). The attractiveness of ADMSCs is characterized by their immunomodulatory activities, regenerative properties, and relative ease of access. ADMSC therapies in a...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Communications Biology |
| Online Access: | https://doi.org/10.1038/s42003-025-08244-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234442059513856 |
|---|---|
| author | Vanshika Sood Hannah Ricioli George Chigozie Njoku Rosita Primavera Susana Dietrich Avnesh S. Thakor Flemming Pociot Reza Yarani |
| author_facet | Vanshika Sood Hannah Ricioli George Chigozie Njoku Rosita Primavera Susana Dietrich Avnesh S. Thakor Flemming Pociot Reza Yarani |
| author_sort | Vanshika Sood |
| collection | DOAJ |
| description | Abstract Adipose tissue-derived mesenchymal stromal/stem cells (ADMSCs) represent a novel therapeutic intervention for Type 1 Diabetes (T1D). The attractiveness of ADMSCs is characterized by their immunomodulatory activities, regenerative properties, and relative ease of access. ADMSC therapies in animal models and clinical trials have revealed decreased insulin dependence, increased β cell mass, and improved islet graft acceptance. Despite their potential, challenges in quality control, small-scale investigations, functional heterogeneity, and standardization limit the application of these therapies. This review synthesizes the current knowledge and recent outcomes of ADMSC therapies in treating T1D and highlights areas that need further investigation. |
| format | Article |
| id | doaj-art-671b1f2928ee4c35ab196e9fb6fbbe05 |
| institution | Kabale University |
| issn | 2399-3642 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Biology |
| spelling | doaj-art-671b1f2928ee4c35ab196e9fb6fbbe052025-08-20T04:03:07ZengNature PortfolioCommunications Biology2399-36422025-07-018111710.1038/s42003-025-08244-zAdipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatmentVanshika Sood0Hannah Ricioli1George Chigozie Njoku2Rosita Primavera3Susana Dietrich4Avnesh S. Thakor5Flemming Pociot6Reza Yarani7Translational Type 1 Diabetes Research, Department of Clinical and Translational Research, Steno Diabetes Center CopenhagenTranslational Type 1 Diabetes Research, Department of Clinical and Translational Research, Steno Diabetes Center CopenhagenTranslational Type 1 Diabetes Research, Department of Clinical and Translational Research, Steno Diabetes Center CopenhagenInterventional Radiology Innovation at Stanford (IRIS), Department of Radiology, School of Medicine, Stanford UniversityDepartment of Science & Health, DIS Study Abroad in ScandinaviaInterventional Radiology Innovation at Stanford (IRIS), Department of Radiology, School of Medicine, Stanford UniversityTranslational Type 1 Diabetes Research, Department of Clinical and Translational Research, Steno Diabetes Center CopenhagenTranslational Type 1 Diabetes Research, Department of Clinical and Translational Research, Steno Diabetes Center CopenhagenAbstract Adipose tissue-derived mesenchymal stromal/stem cells (ADMSCs) represent a novel therapeutic intervention for Type 1 Diabetes (T1D). The attractiveness of ADMSCs is characterized by their immunomodulatory activities, regenerative properties, and relative ease of access. ADMSC therapies in animal models and clinical trials have revealed decreased insulin dependence, increased β cell mass, and improved islet graft acceptance. Despite their potential, challenges in quality control, small-scale investigations, functional heterogeneity, and standardization limit the application of these therapies. This review synthesizes the current knowledge and recent outcomes of ADMSC therapies in treating T1D and highlights areas that need further investigation.https://doi.org/10.1038/s42003-025-08244-z |
| spellingShingle | Vanshika Sood Hannah Ricioli George Chigozie Njoku Rosita Primavera Susana Dietrich Avnesh S. Thakor Flemming Pociot Reza Yarani Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment Communications Biology |
| title | Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment |
| title_full | Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment |
| title_fullStr | Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment |
| title_full_unstemmed | Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment |
| title_short | Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment |
| title_sort | adipose derived mesenchymal stromal stem cells in type 1 diabetes treatment |
| url | https://doi.org/10.1038/s42003-025-08244-z |
| work_keys_str_mv | AT vanshikasood adiposederivedmesenchymalstromalstemcellsintype1diabetestreatment AT hannahricioli adiposederivedmesenchymalstromalstemcellsintype1diabetestreatment AT georgechigozienjoku adiposederivedmesenchymalstromalstemcellsintype1diabetestreatment AT rositaprimavera adiposederivedmesenchymalstromalstemcellsintype1diabetestreatment AT susanadietrich adiposederivedmesenchymalstromalstemcellsintype1diabetestreatment AT avneshsthakor adiposederivedmesenchymalstromalstemcellsintype1diabetestreatment AT flemmingpociot adiposederivedmesenchymalstromalstemcellsintype1diabetestreatment AT rezayarani adiposederivedmesenchymalstromalstemcellsintype1diabetestreatment |